Vanflyta (quizartinib)

pCPA File Number: 23242

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with standard cytarabineand anthracycline induction and standard cytarabine consolidationchemotherapy, and as continuation maintenance monotherapy followingconsolidation, for the treatment of adult patients with newly diagnosed acutemyeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandemduplication (FLT3-ITD) positive.

Sponsor/Manufacturer:

Daiichi Sankyo Pharma Canada

CDA-AMC Project Number:

PC0359-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable